Last reviewed · How we verify
SB204 4%
SB204 4% is a topical nitric oxide-releasing agent.
SB204 4% is a topical nitric oxide-releasing agent. Used for Acne vulgaris.
At a glance
| Generic name | SB204 4% |
|---|---|
| Also known as | NVN1000 |
| Sponsor | Novan, Inc. |
| Drug class | nitric oxide-releasing agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It works by releasing nitric oxide, which has antimicrobial and anti-inflammatory properties, to treat acne.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
Key clinical trials
- P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (PHASE3)
- P3 Study in Acne Comparing Once Daily SB204 and Vehicle (PHASE3)
- P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (PHASE2)
- P3 Long Term Safety Study of Once Daily SB204 in Acne (PHASE3)
- A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (PHASE1)
- A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel (PHASE1)
- A Phase 1 Study Assessing Local Cutaneous Effects of SB204 (PHASE1)
- Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB204 4% CI brief — competitive landscape report
- SB204 4% updates RSS · CI watch RSS
- Novan, Inc. portfolio CI